VIRACTA THERAPEUTICS, INC. Inactive Instrument
Viracta Therapeutics, Inc. Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Presentation Operator MessageOperator (Operator)Welcome to Sunesis Pharmaceuticals Third Quart...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +22.81% | 47.9B | |
| +46.56% | 41.42B | |
| -1.88% | 40.7B | |
| -6.20% | 28.92B | |
| +11.33% | 25.55B | |
| -21.00% | 19.27B | |
| -1.43% | 12.15B | |
| +30.73% | 12.14B | |
| -0.48% | 11.99B |
